Search

This article describes the rationale, study design, and implementation for the Step'n Out study of the Criminal Justice Drug Abuse Treatment Studies. Step'n Out tests the relative effectiveness of collaborative behavioral management of drug-involved parolees. Collaborative behavioral management integrates the roles of parole officers and treatment counselors to provide role induction counseling, contract for pro-social behavior, and deliver contingent reinforcement of behaviors consistent with treatment objectives. The Step'n Out study will randomize 450 drug-involved parolees to collaborative behavioral management or usual parole. Follow-up at 3-and 9-months will assess primary outcomes of rearrest, crime and drug use. If collaborative behavioral management is effective, its wider adoption could improve the outcomes of community reentry of drug-involved ex-offenders. (Contains 4 tables.)

Describes a statewide program that integrated university research, extension, state agencies, private groups, and individual farmers/businesses into a planning process for the future of rural resources. Discusses the resulting planning conference and published report. (SK)

ABSTRACT Aims To determine whether collaborative behavioral management (CBM) reduces substance use, crime and re-arrest among drug-involved parolees. Design Step'n Out was a randomized behavioral trial of CBM versus standard parole (SP) during 2004-08. CBM adapted evidence-based role induction, behavioral contracting and contingent reinforcement to provide parole officer/treatment counselor dyads with positive tools in addition to sanctions to manage parolees' behavior over 12 weeks. Setting Six parole offices in five states in the USA. Participants Parolee volunteers with a mandate for addiction treatment and a minimum of 3 months of parole ( n = 476). Follow-up was 94% at 3 months and 86% at 9 months. Measurements Drug use and crime in a given month from calendar interviews 3 and 9 months after parole initiation, and re-arrests from criminal justice administrative data. Findings The CBM group had fewer months in which they used their primary drug [adjusted risk ratio (ARR) 0.20, 95% confidence interval (CI): 0.05, 0.78, P = 0.02] and alcohol (ARR 0.38, 95% CI: 0.22, 0.66, P = 0.006) over follow-up. CBM had its greatest effects among parolees who reported marijuana or another 'non-hard' drug as their primary drug; parolees who preferred stimulants or opiates did not benefit. No differences were seen in total crime, re-arrests or parole revocations. Conclusions Collaborative behavioral management may reduce substance use among primary marijuana or other 'non-hard' drug-using parolees without increasing revocations. Because the majority of drug violation arrests in the United States are for marijuana, these findings have important implications for the management of a substantial proportion of the US community correctional population. [ABSTRACT FROM AUTHOR]

Objectives: Incarceration is widely believed to be unnecessary and harmful for criminal defendants with psychiatric disorders, most of whom have co-occurring substance use problems. An increasingly popular approach for such defendants is diversion away from the criminal justice system and into treatment. In this article, we present the findings of a quasi-experimental study evaluating the post-booking, arraignment court-based model of diversion used in Connecticut. To improve upon previous quasi-experimental studies, we employ propensity scoring to compare similar defendants from courts with diversion and with no diversion programs. Methods: Persons with serious mental illness and co-occurring substance use disorders were recruited into the study from among criminal defendants in seven criminal courts with diversion programs (n = 113) and five courts without diversion programs (n = 98). Structured research interviews, including measures of mental health, substance use, criminal involvement, employment, and quality of life, were conducted at baseline and at 3 and 12 months following baseline. Additional data was collected from administrative sources in the correctional department and court system. Results: The most striking differences between the diversion and the comparison groups were that the diversion group spent significantly fewer days incarcerated in the year following the index arrest, and were also less likely to be re-incarcerated. Grouping by time differences also suggests greater improvements in life satisfaction favoring the diversion group. Conclusions: Post-booking diversion programs can successfully divert individuals with co-morbid psychiatric and substance use without increased risk to the individual or the community, and with modest improvements in life satisfaction for the defendant. [ABSTRACT FROM AUTHOR]

Background: An open-label, randomized controlled trial compared clozapine with physicians'-choice medications among long-term state hospital inpatients in Connecticut. The goal was to examine clozapine's cost-effectiveness in routine practice for people experiencing lengthy hospitalizations. Methods: Long-stay patients with schizophrenia in a state hospital were randomly assigned to begin open-label clozapine (n = 138) or to continue receiving conventional antipsychotic medications (n = 89). We interviewed study participants every 4 months for 2 years to assess psychiatric symptoms and functional status, and we collected continuous measures of prescribed medications, service utilization, and other costs. We used both parametric and nonparametric techniques to examine changes in cost and parametric analyses to examine changes in effectiveness. We used bootstrap techniques to estimate incremental cost-effectiveness ratios and create cost-effectiveness acceptability curves. Results: Both groups incurred similar costs during the 2-year study period, with a trend for clozapine to be less costly than usual care in the second study year. Clozapine was more effective than usual care on many but not all measures. With the use of effectiveness measures that favored clozapine (extrapyramidal side effects, disruptiveness), bootstrap techniques indicated that, even when a payer is unwilling to incur any additional cost for gains in effectiveness, the probability that clozapine is more cost-effective than usual care is at least 0.80. These findings were not as evident when outcomes where clozapine was not clearly superior (psychotic symptoms, weight gain) were examined. Conclusion: Clozapine demonstrated cost-effectiveness on some but not all measures of effectiveness when the alternative was a range of conventional antipsychotic medications. [ABSTRACT FROM AUTHOR]

Clients who were high service users with serious mental disorders were randomly assigned to assertive community treatment (ACT) or to standard case management (SCM) at three sites and followed for 18 months. Clients in ACT spent more days in the community than did those in SCM, at no additional cost. For clients who were hospitalized at study entry, assertive community treatment was more cost-effective than standard case management. [ABSTRACT FROM AUTHOR]

Early intervention may improve long-term outcomes for psychotic illnesses. Early-intervention services in other countries have focused on reducing the duration of untreated illness and adapting interventions for younger patients. This column describes the process of building such a service, called specialized treatment early in psychosis (STEP), at the Connecticut Mental Health Center. This effort is rooted in a longstanding collaborative relationship between the Connecticut Department of Mental Health and Addiction Services and Yale. The authors describe the critical contribution of such partnerships in evaluating the cost-effectiveness of early intervention in a "real-world" U.S. setting. [ABSTRACT FROM AUTHOR]

Adults suffering from a serious mental illness (SMI) and a substance use disorder are at especially high risk for poor clinical outcomes and also arrest and incarceration. Pharmacotherapies for treating opioid dependence could be a particularly important mode of treatment for opioid-dependent adults with SMI to lower their risk for overdose, high-cost hospitalizations, repeated emergency department visits, and incarceration, given relapse rates are very high following detoxification in the absence of one of the three FDA-approved pharmacotherapies. This study estimates the effects of methadone, buprenorphine, and oral naltrexone on clinical and justice-related outcomes in a sample of justice-involved adults with SMI, opioid dependence, and criminal justice involvement. Administrative data were merged from several public agencies in Connecticut for 8736 adults 18years of age or older with schizophrenia spectrum disorder, bipolar disorder, or major depression; co-occurring moderate to severe opioid dependence; and who also had at least one night in jail during 2002-2009. Longitudinal multivariable regression models estimated the effect of opioid-dependence pharmacotherapy as compared to outpatient substance abuse treatment without opioid-dependence pharmacotherapy on inpatient substance abuse or mental health treatment, emergency department visits, criminal convictions, and incarcerations, analyzing instances of each outcome 12months before and after an index treatment episode. Several baseline differences between the study groups (opioid-dependence pharmacotherapy group versus outpatient treatment without opioid-dependence pharmacotherapy) were adjusted for in the regression models. All three opioid-dependence pharmacotherapies were associated with reductions in inpatient substance abuse treatment, and among the oral naltrexone subgroup, also reductions in inpatient mental health treatment, as well as improved adherence to SMI medications. Overall, the opioid-dependence pharmacotherapy group had higher rates of arrest and incarceration in the follow-up period than the comparison group; but those using oral naltrexone had lower rates of arrest (including felonies). The analysis of observational administrative data provides useful population-level estimates but also has important limitations that preclude conclusive causal inferences. Large reductions in crisis-driven service utilization associated with opioid-dependence pharmacotherapy in this study suggest that evidence-based medications for treating opioid dependence can be used successfully in adults with SMI and should be considered more systematically during assessments of treatment needs for this population. [ABSTRACT FROM AUTHOR]

The article discusses various aspects of Connecticut's Public Act 99-212 which was passed in response to a mass murder shooting incident in the state in 1998 and the Columbine school shooting massacre in Colorado, and it examines whether Connecticut's risk-based firearm (gun) removal law is effective and prevents suicides. According to the article, Connecticut is the first American state to authorize the seizure of firearms from dangerous individuals before they have committed acts of violence.

The impact of criminal justice involvement and clinical characteristics on the cost of public treatment services for adults with serious mental illnesses is unknown. The authors examined differential effects of justice involvement on behavioral health treatment costs by primary psychiatric diagnosis (schizophrenia or bipolar disorder) and also by substance use diagnosis among 25,133 adult clients of Connecticut's public behavioral health system in fiscal years 2006 and 2007. Justice-involved adults with schizophrenia had the highest costs, strongly driven by forensic hospitalizations. Addressing the cross-system burdens of forensic hospitalizations may be a sensible starting point in the effort to reduce costs in both the public behavioral health and justice systems.

Objective: Jail diversion programs strive to divert offenders with mental illness from prosecution and into mental health treatment. Participants sometimes spend a short time in jail after arraignment, either because treatment resources are not immediately available or because judges want to increase their motivation for treatment. This study explored the effects of short jail stays before jail diversion ("jail first") on participants' postdiversion service use and reoffending., Methods: The data were merged administrative records from public behavioral health and criminal justice systems in Connecticut for 712 adults with serious mental illness who participated in the jail diversion program during fiscal years 2005-2007. The effects on treatment receipt, crisis-driven service use, and reoffending during the six months postdiversion among jail first participants (N=102) versus a propensity-matched sample of participants who were diverted immediately (N=102) were estimated., Results: Jail first participants had greater improvements in receipt of psychotropic medication during the follow-up compared with their counterparts who were diverted immediately. However, compared with participants who were immediately diverted, they did not have greater reductions in crisis-driven service use or reoffending and the time to reincarceration was shorter., Conclusions: Short stays in jail before diversion did not appear to be associated with improved mental health and reoffending outcomes, even though they appeared to improve receipt of psychotropic medication. Further research is needed to better understand the relationships between jail first, receipt of psychotropic medication, and broader health and offending outcomes, with a focus on identifying missing links that address criminogenic risks and participants' more intensive social service needs.

Early intervention may improve long-term outcomes for psychotic illnesses. Early-intervention services in other countries have focused on reducing the duration of untreated illness and adapting interventions for younger patients. This column describes the process of building such a service, called specialized treatment early in psychosis (STEP), at the Connecticut Mental Health Center. This effort is rooted in a long-standing collaborative relationship between the Connecticut Department of Mental Health and Addiction Services and Yale. The authors describe the critical contribution of such partnerships in evaluating the cost-effectiveness of early intervention in a "real-world" U.S. setting.